Classification and regression tree analysis for the prediction of aggressive prostate cancer on biopsy

Journal of Urology

Volumn 175, Issue 3, 2006, Pages 918-922

  Spurgeon, Stephen E F ^a   Hsieh, Yi Ching ^b   Rivadinera, Adrianna ^c   Beer, Tomasz M ^a   Mori, Motomi ^b   Garzotto, Mark ^b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Biopsy; Prostate; Prostate specific antigen; Prostatic neoplasms; Risk

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DEMOGRAPHY; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

AGED; AGED, 80 AND OVER; CHILD; DECISION TREES; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; PROGNOSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 32044452903     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)00353-8     Document Type: Article

References (20)

1. A. Jemal, R.C. Tiwari, T. Murray, A. Ghafoor, A. Samuels, E. Ward Cancer statistics, 2004 CA Cancer J Clin 54 2004 8
2. J.E. Johansson, O. Andren, S.O. Andersson, P.W. Dickman, L. Holmberg, A. Magnuson Natural history of early, localized prostate cancer JAMA 291 2004 2713
3. P.C. Albertsen, J.A. Hanley, D.F. Gleason, M.J. Barry Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer JAMA 280 1998 975
4. C.R. Pound, A.W. Partin, M.A. Eisenberger, D.W. Chan, J.D. Pearson, P.C. Walsh Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591
5. F.H. Schroder, P. van der Maas, P. Beemsterboer, A.B. Kruger, R. Hoedemaeker, J. Rietbergen Rotterdam section of the European Randomized Study of Screening for Prostate Cancer Evaluation of the digital rectal examination as a screening test for prostate cancer J Natl Cancer Inst 90 1998 1817
6. T.A. Stamey, M. Caldwell, J.E. McNeal, R. Nolley, M. Hemenez, J. Downs The prostate specific antigen era in the United States is over for prostate cancer what happened in the last 20 years? J Urol 172 2004 1297
7. I.M. Thompson, D.K. Pauler, P.J. Goodman, C.M. Tangen, M.S. Lucia, H.L. Parnes Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter N Engl J Med 350 2004 2239
8. B. Djavan, M. Remzi, A. Zlotta, C. Seitz, P. Snow, M. Marberger Novel artificial neural network for early detection of prostate cancer J Clin Oncol 20 2002 921
9. J.A. Eastham, R. May, J.L. Robertson, O. Sartor, M.W. Kattan Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL Urology 54 1999 709
10. S.R. Potter, W. Horniger, M. Tinzl, G. Bartsch, A.W. Partin Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer Urology 57 2001 1100
11. M. Garzotto, T.M. Beer, R.G. Hudson, L. Peters, Y.C. Hsieh, E. Barrera Improved detection of prostate cancer using classification and regression tree analysis J Clin Oncol 2005 e-published ahead of print
12. L. Breiman, J. Friedman, R. Olshen, C. Stone Classification and Regression Trees 1984 Wadsworth Pacific Grove, California
13. M.C. Costanza, F. Paccaud Binary classification of dyslipidemia from the waist-to-hip ratio and body mass index a comparison of linear, logistic, and CART models BMC Med Res Methodol 4 2004 7
14. A.N. Vis, R. Kranse, M. Roobol, T.H. van der Kwast, F.H. Schroder Serendipity in detecting disease in low prostate-specific antigen ranges BJU Int 89 2002 384
15. G. Schatzl, S. Madersbacher, T. Thurridl, J. Waldmuller, G. Kramer, A. Haitel High-grade prostate cancer is associated with low serum testosterone levels Prostate 47 2001 52
16. A.V. D'Amico, M.H. Chen, K.A. Roehl, W.J. Catalona Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy N Engl J Med 351 2004 125
17. W.J. Catalona, A.W. Partin, K.M. Slawin, M.K. Brawer, R.C. Flanigan, A. Patel Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease a prospective multicenter clinical trial JAMA 279 1998 1542
18. M.W. Kattan, J.A. Eastham, T.M. Wheeler, N. Maru, P.T. Scardino, A. Erbersdobler Counseling men with prostate cancer a nomogram for predicting the presence of small, moderately differentiated, confined tumors J Urol 170 2003 1792
19. P.D. Sved, P. Gomez, M. Manoharan, S.S. Kim, M.S. Soloway Limitations of biopsy Gleason grade implications for counseling patients with biopsy Gleason score 6 prostate cancer J Urol 172 2004 98
20. I.F. San Francisco, W.C. DeWolf, S. Rosen, M. Upton, A.F. Olumi Extended prostate needle biopsy improves concordance of Gleason grading between prostate needle biopsy and radical prostatectomy J Urol 169 2003 136